Russell Investments Group Ltd. Invests $3.27 Million in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Russell Investments Group Ltd. has invested approximately $3.27 million in Centessa Pharmaceuticals, acquiring 227,598 shares, representing 0.17% of the company.
• Centessa Pharmaceuticals' stock is currently down by 3.0%, with a market capitalization of $2.28 billion and a PE ratio of -9.50.
• Despite recent insider selling, analysts remain optimistic, with many recommending a "buy" rating and a consensus price target of $28.10.

Russell Investments Group Ltd. purchased a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 227,598 shares of the company's stock, valued at approximately $3,273,000. Russell Investments Group Ltd. owned 0.17% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $31,000. Barclays PLC raised its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after buying an additional 4,952 shares during the period. Bank of New York Mellon Corp purchased a new stake in Centessa Pharmaceuticals in the 1st quarter worth about $147,000. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth about $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $171,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Down 3.0%

CNTA stock opened at $17.01 on Friday. The firm has a market cap of $2.28 billion, a PE ratio of -9.50 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $19.09. The company has a fifty day simple moving average of $15.28 and a 200 day simple moving average of $14.51. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Sell-side analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $15.56, for a total transaction of $155,600.00. Following the completion of the sale, the insider owned 122,279 shares of the company's stock, valued at $1,902,661.24. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $17.23, for a total transaction of $103,380.00. Following the completion of the sale, the general counsel owned 105,386 shares of the company's stock, valued at $1,815,800.78. The trade was a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 181,322 shares of company stock valued at $2,601,014 in the last quarter. Company insiders own 7.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price for the company. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target on the stock. Truist Financial initiated coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price objective for the company. Finally, Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Eleven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $28.10.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.